ESMO Symposium on Signalling Pathways in Cancer 2015 – Targeting the MAPK pathway: From RAS to MEK
Barcelona, Spain - 13 Mar - 14 Mar 2015
This meeting will look at the role of MAPK signalling in cancer, and the rationale and strategies for inhibiting the pathway. The MAPK pathway and its inhibition will be reviewed – from the latest in translational research and emerging pathway inhibitors, to clinical trials and approved indications.
- To provide an introduction on preclinical data relevant for the understanding of the functional mechanisms in the PI3K/AKT/mTOR pathway.
- To understand basic concepts of translating preclinical observations in the PI3K/AKT/mTOR signalling pathway into cancer clinics.
- To provide an essential update on different aspects important for rational clinical development of the PI3K/AKT/mTOR inhibitors.
- To explore – from a clinical perspective – recent achievements and data from ongoing clinical trials targeting all axes of the PI3K/AKT/mTOR pathway across a wide range of malignant diseases
Chairs: Solange Peters, Switzerland and Giampaolo Tortora, Italy